SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

Breast Cancer Research and Treatment

Volumn 158, Issue 3, 2016, Pages 485-495

  Nahleh, Z A ^a   Barlow, W E ^b   Hayes, D F ^c   Schott, A F ^c   Gralow, J R ^d   Sikov, W M ^e   Perez, E A ^f,g   Chennuru, S ^h,i   Mirshahidi, H R ^j   Corso, S W ^k   Lew, D L ^b   Pusztai, L ^l   Livingston, R B ^m   Hortobagyi, G N ⁿ  

^a Texas Tech University Health Sciences Center El Paso   (United States)

^b SWOG STATISTICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e BROWN UNIVERSITY   (United States)

^f GENENTECH INC   (United States)

^g MAYO CLINIC   (United States)

^h Hematology Oncology Consultants   (United States)

ⁱ Department of Hematology Oncology   (United States)

^j LOMA LINDA UNIVERSITY HEALTH   (United States)

^k Gibbs Cancer Center and Research Institute Southeast Clinical Oncology Research (SCOR) Consortium NCORP Upstate Carolina CCOP (previous)   (United States)

^l YALE UNIVERSITY   (United States)

^m UNIVERSITY OF ARIZONA   (United States)

ⁿ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Bevacizumab; Breast cancer; Inflammatory; Locally advanced; Neoadjuvant

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; HORMONE RECEPTOR; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84978120241     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-016-3889-6     Document Type: Article

References (49)

1. Chia S, Swain SM, Byrd DR, Mankoff DA (2008) Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786–790
2. Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628–3636
3. Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474
4. Masuda H, Brewer TM, Liu DD et al (2014) Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol 25:384–391
5. Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044
6. Fumagalli D, Bedard PL, Nahleh Z et al (2012) A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol 13:e240–e248
7. von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804
8. Kleer CG, van Golen KL, Merajver SD (2000) Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2:423–429
9. Shirakawa K, Kobayashi H, Sobajima J et al (2003) Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 5:136–139
10. Sledge GW Jr, Rugo HS, Burstein HJ (2006) The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 4:1–10 (quiz 11-12)
11. Wedam SB, Low JA, Yang SX et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769–777
12. Hurwitz H, Kabbinavar F (2005) Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. Oncology 69(Suppl 3):17–24
13. Presta LG, Chen H, O’Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599
14. Miller KD (2003) E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3:421–422
15. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24–40
16. Midgley R, Kerr D (2005) Bevacizumab—current status and future directions. Ann Oncol 16:999–1004
17. Jain RK (2002) Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 29:3–9
18. Lenzer J (2011) FDA committee votes to withdraw bevacizumab for breast cancer. BMJ 343:d4244
19. Cameron D, Brown J, Dent R et al (2013) Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 14:933–942
20. Miller K, O’Neill AM, Dang CT et al (2014) Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: final results from Eastern Cooperative Oncology Group E5103. J Clin Oncol 32:5s (Suppl; abstr 500)
21. Hayes DF (2011) Bevacizumab treatment for solid tumors: boon or bust? JAMA 305:506–508
22. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172–1183
23. Sweeney CJ, Miller KD, Sissons SE et al (2001) The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369–3372
24. Desai N, Trieu V, Yao Z et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317–1324
25. Muller BG, Leuenberger H, Kissel T (1996) Albumin nanospheres as carriers for passive drug targeting: an optimized manufacturing technique. Pharm Res 13:32–37
26. Kim YW, Park YK, Lee J et al (1998) Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 13:652–657
27. Van den Eynden GG, Van Laere SJ, Van der Auwera I et al (2006) Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 95:219–228
28. Link JS, Waisman JR, Nguyen B, Jacobs CI (2007) Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 7:779–783
29. Volk LD, Flister MJ, Chihade D et al (2011) Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. Neoplasia 13:327–338
30. Untch M, Jackisch C, Schneeweiss A et al (2015) A randomized phase III trial comparing neoadjuvant chemotherapy with weekly nanoparticle-based paclitaxel with solvent-based paclitaxel followed by anthracyline/cyclophosphamide for patients with early breast cancer (GeparSepto); GBG 69. Cancer Res 75(9 Suppl):S2-07
31. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
32. Budd GT, Barlow WE, Moore HC et al (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58–64
33. Hutchins LF, Green SJ, Ravdin PM et al (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol 23:8313–8321
34. Martin M, Segui MA, Anton A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363:2200–2210
35. Blum JL, Savin MA, Edelman G et al (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7:850–856
36. Recht A, Edge SB, Solin LJ et al (2001) Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539–1569
37. Ellis GK, Barlow WE, Gralow JR et al (2011) Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014–1021
38. Green S, Benedetti J, Smith A (2012) Clinical trials in oncology, 3rd edn. CRC Press, Bocca Raton
39. Yardley DA (2013) nab-Paclitaxel mechanisms of action and delivery. J Control Release 170:365–372
40. Earl HM, Hiller L, Dunn JA et al (2015) Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol 16:656–666
41. von Minckwitz G, Eidtmann H, Rezai M et al (2012) Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 366:299–309
42. Bear HD, Tang G, Rastogi P et al (2012) Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med 366:310–320
43. Sikov WM, Berry DA, Perou CM et al (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33:13–21
44. Bear HD, Tang G, Rastogi P et al (2015) Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol 16:1037–1048
45. Lambrechts D, Lenz HJ, de Haas S et al (2013) Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 31:1219–1230
46. Sikov WM, Barry WT, Hoadley KA et al (2015) Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) plus/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc). Cancer Res 75(9 Suppl):S4–05
47. Tredan O, Lacroix-Triki M, Guiu S et al (2015) Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol 10:189–198
48. Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508–1516
49. Korn EL, Sachs MC, McShane LM (2015) Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer. Ann Oncol 27(1):10–15